Literature DB >> 26255210

Strategies targeting the IL-4/IL-13 axes in disease.

Richard D May, Michael Fung.   

Abstract

IL-4 and IL-13 are pleiotropic Th2 cytokines produced by a wide variety of different cell types and responsible for a broad range of biology and functions. Physiologically, Th2 cytokines are known to mediate host defense against parasites but they can also trigger disease if their activities are dysregulated. In this review we discuss the rationale for targeting the IL-4/IL-13 axes in asthma, atopic dermatitis, allergic rhinitis, COPD, cancer, inflammatory bowel disease, autoimmune disease and fibrotic disease as well as evaluating the associated clinical data derived from blocking IL-4, IL-13 or IL-4 and IL-13 together.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26255210     DOI: 10.1016/j.cyto.2015.05.018

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  50 in total

1.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

2.  Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease.

Authors:  Abdullah Kursat Cingu; Fatih Mehmet Turkcu; Serdar Aktas; Alparslan Sahin; Orhan Ayyildiz
Journal:  Int Ophthalmol       Date:  2020-07-29       Impact factor: 2.031

3.  Snapshots of CD4+ T cell plasticity in the pathogenesis of allergic asthma.

Authors:  Wook-Jin Chae; Alfred L M Bothwell
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  Construction of genetically modified Lactococcus lactis that produces bioactive anti-interleukin-4 single-chain fragment variable.

Authors:  Fu Namai; Suguru Shigemori; Tasuku Ogita; Takashi Sato; Takeshi Shimosato
Journal:  Mol Biol Rep       Date:  2020-09-02       Impact factor: 2.316

5.  A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABAA Receptors in the Lung.

Authors:  Gloria S Forkuo; Amanda N Nieman; Revathi Kodali; Nicolas M Zahn; Guanguan Li; M S Rashid Roni; Michael Rajesh Stephen; Ted W Harris; Rajwana Jahan; Margaret L Guthrie; Olivia B Yu; Janet L Fisher; Gene T Yocum; Charles W Emala; Douglas A Steeber; Douglas C Stafford; James M Cook; Leggy A Arnold
Journal:  Mol Pharm       Date:  2018-04-02       Impact factor: 4.939

6.  Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients.

Authors:  Ting Li; Li Gao; Hong-Xia Ma; Yang-Yang Wei; Yue-Hua Liu; Ke-Ru Qin; Wen-Tao Wang; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-03

Review 7.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

8.  Soluble interleukin-13rα1: a circulating regulator of glucose.

Authors:  Inbal Rachmin; Caitlin C O'Meara; Elisabeth M Ricci-Blair; Yilin Feng; Emily M Christensen; Jeanne F Duffy; Kirsi M Zitting; Charles A Czeisler; James R Pancoast; Christopher P Cannon; Michelle L O'Donoghue; David A Morrow; Richard T Lee
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-09-05       Impact factor: 4.310

9.  Hierarchical control of interleukin 13 (IL-13) signals in lung fibroblasts by STAT6 and SOX11.

Authors:  Yasutaka Mitamura; Satoshi Nunomura; Yasuhiro Nanri; Kazuhiko Arima; Tomohito Yoshihara; Kosaku Komiya; Shogo Fukuda; Hiroaki Takatori; Hiroshi Nakajima; Masutaka Furue; Kenji Izuhara
Journal:  J Biol Chem       Date:  2018-08-03       Impact factor: 5.157

Review 10.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Maria Gabriella Matera; Clive Page; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.